Eiger BioPharmaceuticals, Inc.
EIGR
Rang in aandelen
#36446
Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company... Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and bringing to market targeted therapies for rare and ultra-rare diseases across the United States and internationally. Its primary investigational drug, Lonafarnib, an orally administered small molecule, is currently undergoing Phase III clinical trials for the treatment of hepatitis delta virus (HDV) infection. Other promising candidates in its portfolio include Lambda, which has completed Phase II clinical trials and is designed to target type III interferon receptors; Lonafarnib, also being evaluated for progeria and progeroid laminopathies; and Avexitide, an agent for congenital hyperinsulinism that has also successfully concluded Phase II studies for post-bariatric hypoglycemia. Established in 2008, Eiger BioPharmaceuticals, Inc. maintains its headquarters in Palo Alto, California.
Aandeelprijs
$1.73
Laatst gesynchroniseerd: 2025-06-17
Marktkapitalisatie
$2.55M
Verandering (1 dag)
-0.29%
Verandering (1 jaar)
-79.71%
Land
US
Handel Eiger BioPharmaceuticals, Inc. (EIGR)
Categorie
Healthcare
EPS voor Eiger BioPharmaceuticals, Inc. (EIGR)
EPS per December 2023 TTM: $-50.79
Volgens de laatste financiële rapporten en de aandelenkoers van Eiger BioPharmaceuticals, Inc. is de huidige EPS van het bedrijf (TTM) $-50.79. Eind 2022 had het bedrijf een EPS van $-69.74, een stijging ten opzichte van de EPS van 2021 die $-29.98 bedroeg.
EPS-geschiedenis van Eiger BioPharmaceuticals, Inc. van 2016 tot 2026
EPS aan het einde van elk jaar
| Jaar | EPS | Wijzigen |
|---|---|---|
| 2026 (TTM) | $-50.79 | 0.02% |
| 2023 | $-50.78 | -27.19% |
| 2022 | $-69.74 | 132.62% |
| 2021 | $-29.98 | -56.76% |
| 2020 | $-69.34 | -25.04% |
| 2019 | $-92.50 | -19.31% |
| 2018 | $-114.63 | -21.43% |
| 2017 | $-145.90 | -37.96% |
| 2016 | $-235.16 | 0.00% |
EPS van vergelijkbare bedrijven of concurrenten
| Bedrijf | EPS | EPS-verschil | Land |
|---|---|---|---|
| $17.32 | -134.10% |
US
|
|
| $-7.98 | -84.29% |
US
|
|
| $-5.29 | -89.58% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -154.62% |
NL
|
